Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: Endo | Rare Historical Photos

ENDO 2026 Study Finds Most People Who Stop Ozempic or Tirzepatide for Type 2 Diabetes Eventually Restart Treatment

ENDO 2026 research published June 2026 via ScienceDaily found most GLP-1 users with type 2 diabetes who stop treatment eventually restart, driven by weight regain.

Medical Daily

I’ve Struggled With Debilitating Endometriosis Symptoms for Years – 7 Facts I Wish I’d Known Sooner

From diagnosis delays to misconceptions about fertility, here's what I've learnt living with endometriosis.

Marie Claire

Kanpai! Discover the best bars to drink sake in London

Discover the best bars in London to celebrate this ancient delight, just in time for World Sake Day on October 1st

Wallpaper

From analysis to the latest developments in health,
read the most diverse news in one place.

My London: David Baddiel

The writer and comedian marvels at the Rothko Room at Tate Modern, has tried the posh sushi at Endo… and still has Three Lions on his shirt

Evening Standard

Opioid maker Endo to be monitored by Obama's former drug czar for $25K a month

Under pressure from people impacted by the nation's ongoing opioid crisis, a New York judge has confirmed Gil Kerlikowske, a former national drug czar in the Obama administration, as an outside monitor over Endo International's opioid business. The Chester County drug firm is reorganizing in bankruptcy court.

The Philadelphia Inquirer

Opioid-maker Endo $98 million bonuses are delayed in bankruptcy court

A bankruptcy judge on Thursday approved paying $93,000 in short-term incentives to employees and sales reps at Endo International but delayed a broader decision on big bonuses to corporate insiders and others.

The Philadelphia Inquirer

Woman whose horrifying periods saw her bleed every day for 11 months finally gets answer

Morag Smith, 27, has suffered with horrendous periods since she was 16. She was told by doctors that it was just something she would have to deal with but a chance encounter with a colleague saw her determined to get the diagnosis she deserved

Daily Mirror

Read news from The Economist, FT, and more,
with one subscription

Opioid maker Endo paid top executives $55.5 million in bonuses before bankruptcy

Days before the money-losing opioid drug firm Endo International filed for bankruptcy last week, the company paid chief executive Blaise Coleman an $11.85 million bonus.

The Philadelphia Inquirer

Endo, a PA opioid maker, files for bankruptcy with billions in debt

Endo International, one of the nation's larger opioid makers and with U.S. headquarters in Malvern, filed for bankruptcy protection in Manhattan on Tuesday, beset by $9.5 billion in total debt and threatened by thousands of opioid lawsuits.

The Philadelphia Inquirer

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

Benzinga

The Daily Biotech Pulse: FDA Signs Off Cancer Therapy Trials For NexImmune, Omega Therapeutics, Endo To Develop Rare Hereditary Skin Disease Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Why Endo International Shares Are Getting Hammered Today

Endo International PLC (NASDAQ: ENDP) shares are trading lower by 16.86% to $0.39 after the company provided top-line results from its Phase 2 study of CCH in patients with adhesive capsulitis of the shoulder, saying "the difference compared to those study participants receiving placebo was not st

Benzinga

Endo Posts Disappointing Data From Frozen Shoulder Trial

Endo International plc (NASDAQ:ENDP) has announced topline results from its Phase 2 study of collagenase clostridium histolyticum (CCH) in participants with adhesive capsulitis (AC) of the shoulder (frozen shoulder). While participants receiving up to three doses of CCH showed some improvement in the change from baseline in the shoulder pathology composite score, the…

Benzinga

Endo Inks US Pact For Osteoarthritis Pain Injectable

TLC BioSciences has entered a commercialization agreement with Endo International plc (NASDAQ:ENDP) for the U.S. rights of TLC599, a proprietary BioSeizer sustained-release injectable in Phase 3 development for osteoarthritis pain. Under the agreement signed with Endo's subsidiary Endo Ventures Limited (EVL), TLC will primarily be responsible for developing the product, and EVL for obtaining regulatory…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What Is Happening With Endo Shares Today

Endo International Plc (NASDAQ:ENDP) initiated negotiations with its lenders and senior bondholders regarding a possible reorganization of more than $8 billion of its debt, the Wall Street Journal reported, citing people familiar with the matter. Lenders began talks after the company reported disappointing earnings early this month for 1Q 2022, driven by the loss…

Benzinga

Endo Shares Plummet On Decreasing Sales, Wider Loss; Outlook Lagging Consensus

Endo International plc's (NASDAQ:ENDP) Q1 sales decreased 9% to $652.26 million, beating the consensus of $633.41 million. The decrease was attributable to decreased revenues from the sterile injectables segment, partially offset by increased revenues from the generic segment and the specialty products portfolio. Adjusted income from continuing operations reached $156 million compared…

Benzinga

Washington, Drug Distributors Reach $518M Settlement For Opioid Claims

Washington has reached a $518 million settlement with drug distributors McKesson Corporation (NYSE:MCK), AmerisourceBergen Corp (NYSE:ABC), and Cardinal Health Inc (NYSE:CAH) to resolve opioid-related claims. Washington opted out of a $26 billion nationwide opioid settlement involving the three drug distributors and Johnson & Johnson (NYSE:JNJ). Reuters writes that it would…

Benzinga

Endo Acquires Six Development-Stage, Injectable Product Candidates For $35M

Endo International plc (NASDAQ: ENDP) has acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc, a subsidiary of Nevakar Inc.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

San Francisco To Start Opioid Epidemic Trial Against Teva, Walgreen: Reuters

San Francisco will start a trial against Walgreens Boots Alliance Inc (NASDAQ:WBA) and three other companies accused of fueling an opioid crisis in the city. San Francisco has alleged that Walgreens, Teva Pharmaceutical Industries Ltd (NYSE:TEVA), AbbVie Inc's (NYSE:ABBV) Allergan unit, and Teva-owned Anda Inc created a "public nuisance" by flooding the city with prescription opioids and failing…

Benzinga

JNJ, McKesson, Endo Settle $275M Opioid Claims With Alabama: Reuters

Alabama reached $276 million in settlements with Johnson & Johnson (NYSE:JNJ), McKesson Corporation (NYSE:MCK), and Endo International Plc (NASDAQ:ENDP), resolving claims on the opioid addiction crisis, the state attorney general said. McKesson will pay $141 million. JNJ and Endo will pay $70.3 million and $25 million, respectively, Alabama Attorney General Steve Marshall said in a statement. The three…

The Independent UK

Florida secures $860M from CVS, others to settle opioid case

The CVS drug store company and pharmaceutical companies will pay Florida a combined $860 million as part of the settlement of an opioid epidemic case

Benzinga

Barclays Downgrades Endo On 'Difficult Path'

Barclays has downgraded

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.